M Elisa Vink-Borger
Overview
Explore the profile of M Elisa Vink-Borger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grolleman J, de Voer R, Elsayed F, Nielsen M, Weren R, Palles C, et al.
Cancer Cell
. 2019 Feb;
35(2):256-266.e5.
PMID: 30753826
Biallelic germline mutations affecting NTHL1 predispose carriers to adenomatous polyposis and colorectal cancer, but the complete phenotype is unknown. We describe 29 individuals carrying biallelic germline NTHL1 mutations from 17...
2.
van Heumen B, Roelofs H, Vink-Borger M, Dekker E, Mathus-Vliegen E, Dees J, et al.
Orphanet J Rare Dis
. 2013 Aug;
8:118.
PMID: 23919274
Background: Due to prophylactic colectomy, mortality in patients with familial adenomatous polyposis (FAP) has changed, with duodenal cancer currently being the main cause of death. Although celecoxib reduces duodenal polyp...
3.
Mekenkamp L, Tol J, Dijkstra J, de Krijger I, Vink-Borger M, van Vliet S, et al.
BMC Cancer
. 2012 Jul;
12:292.
PMID: 22804917
Background: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve...
4.
Mekenkamp L, Haan J, Koopman M, Vink-Borger M, Israeli D, Teerenstra S, et al.
Gut
. 2012 Jan;
62(1):94-101.
PMID: 22267596
Objective: Metastatic colorectal cancer (CRC) cells have a selective preference for certain target organs that cannot be explained by circulatory patterns alone. This study aimed to identify clinicopathological features and...
5.
Tol J, Dijkstra J, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger M, et al.
Eur J Cancer
. 2010 Apr;
46(11):1997-2009.
PMID: 20413299
Background: Anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC) treatment are only effective in patients with KRAS wild type tumours. Here we assess the predictive value of other potential relevant...